Incentives for Clinical Trialists to Share Data

Clinical trialists' concerns about data sharing can be addressed through steps such as provision of necessary resources, appropriate acknowledgment and academic rewards, clarification of secondary investigators' responsibilities, and collaboration among investigators. Sharing of data from...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 375; no. 12; pp. 1112 - 1115
Main Authors Lo, Bernard, DeMets, David L
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 22.09.2016
Subjects
Access to Information
Clinical trials
Clinical Trials as Topic
Datasets
Information Dissemination
Information sharing
Pharmaceutical industry
Online AccessGet full text

Cover

More Information
Summary:Clinical trialists' concerns about data sharing can be addressed through steps such as provision of necessary resources, appropriate acknowledgment and academic rewards, clarification of secondary investigators' responsibilities, and collaboration among investigators. Sharing of data from clinical trials benefits patients by enabling new discoveries, meta-analyses, and confirmation of published results. As the table shows, the European Medicines Agency (EMA), a number of drug companies, and one other trial funder have already implemented data sharing. A comprehensive Institute of Medicine (IOM) report recommends the sorts of data that should be shared, how long after a trial, and under what conditions. 1 The International Committee of Medical Journal Editors (ICMJE) proposes that the analytic data set supporting a published article be shared no later than 6 months after publication. 2 Others propose longer periods of exclusive data . . .
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMp1608351